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BY-NC-ND license (http://creativecomBackground/Purpose: While new direct-acting antiviral therapies for hepatitis C virus (HCV)
are the standard of care, interferon-a (IFN-a) remains a standard therapy in Taiwan based
on its low cost and high response rate to IFN-a-based therapy. IFN-a exerts antiviral activity
by inducing the expression of hundreds of genes that establish an antiviral state via Jak kinase
(JAK)/signal transducers and activators of transcription (STAT) signaling. We quantified the
transcript levels of JAK/STAT signaling genes in peripheral blood mononuclear cells of HCV ge-
notype 1 patients and estimated the correlation between transcript levels and patient re-
sponses to IFN-a-based therapy.
Methods: A total of 100 HCV genotype 1 naı¨ve patients were enrolled. All patients received
response-guided therapy for 24e48 weeks with pegylated IFN-a and ribavirin. Peripheral blood
mononuclear cells were collected before treatment. Twenty patients with sustained virolog-
ical responses (SVR) and 20 patients without SVR were selected for a JAK/STAT signaling genes
transcript analysis using multiplex reverse transcription-polymerase chain reaction. Tran-
scripts that were upregulated or downregulated were further validated in 100 patients.
Results: Suppressor of cytokine signaling 1 (SOCS1) expression was upregulated in SVR patients
compared with non-SVR patients (relative quantificationZ 2.14) based on a multiplex reverse
transcription-polymerase chain reaction analysis. We further analyzed SOCS1 expression in 100
patients. We found that SOCS1 expression did not differ significantly between SVR and non-SVR
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SOCS-1 in HCV genotype 1 patients 441Conclusion: Peripheral blood SOCS1 expression before treatment was not associated with SVR
in HCV genotype 1 patients treated with pegylated IFN-a and ribavirin.
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nc-nd/4.0/).Introduction
Hepatitis C virus (HCV) is among the leading causes of
chronic liver disease worldwide and affects approximately
170 million people.1e3 The severity of the disease associated
with HCV infection varies from an asymptomatic chronic
infection to cirrhosis and hepatocellular carcinoma.1,4,5
While new direct-acting antiviral therapies are the
standard of care in the American Association for the Study of
Liver Diseases and European Association for the Study of the
Liver guidelines,6,7 interferons (IFNs) will likely remain a
part of the standard therapy for most patients worldwide
because it is cost-effective. Currently, pegylated IFN-a
(PEG-IFN) combined with ribavirin (RBV) is the standard of
care for chronic hepatitis C in Taiwan.8 HCV genotype 1 is
prevalent in Taiwan and worldwide8,9; it is predictive of a
poor response to PEG-IFN and RBV therapy. Previous studies
have demonstrated that sustained virological response (SVR)
rates achieved with the combination therapy are 54e65% for
genotype 1 and 80e95% for genotype 2 patients.10e12
IFNs are central mediators of immune responses to viral
infections.13 IFN-a activity is mediated by its high-affinity
binding to IFN-a receptor and the subsequent induction of
the Jak kinase (JAK)-signal transducers and activators of
transcription (STAT) signaling pathway, which activates the
transcription of >100 genes that establish an antiviral state
in cells.14
Previous studies have investigated hepatic JAK/STAT
signaling in HCV-infected patients,15,16 but few have
investigated peripheral blood JAK/STAT signaling in HCV-
infected patients.17,18 However, gene expression analyses
using liver biopsy specimens are not convenient owing to
the invasive procedure that is required.
Based on the significance of JAK/STAT signaling in IFN-
mediated antiviral responses, the aims of this study were to
quantify JAK/STAT signaling transcripts in peripheral blood
mononuclear cells (PBMCs) of HCV genotype 1 patients and
to estimate the correlation between transcript levels and
patient responses to IFN-a based therapy.Patients and methods
Patients
One hundred HCV genotype 1 naı¨ve patients were enrolled
in the study. The response-guided therapy was as follows:
24 weeks of PEG-IFN and RBV treatment for patients with
undetectable HCV RNA at Week 4 (defined as rapid viro-
logical response); 48 weeks of treatment for patients with
detectable HCV RNA at Week 4 and undetectable HCV RNA
at Week 12 (defined as early virological response); and16 weeks for patients with detectable HCV RNA at Week 12.
SVR was defined as undetectable HCV RNA at follow-up
Week 24. PEG-IFN-a-2b (1.5 mg/kg, Peg-Intron; Schering-
Plough Corporation, Kenilworth, NJ, USA) or PEG-IFN-a-2a
(180 mg, PEGASYS, Roche, Basel, Switzerland) were
administered subcutaneously once weekly. RBV (Rebetol,
Schering-Plough, Auxerre, France) was given at 1000 mg/
d for patients with a body weight of  75 kg and 1200 mg/
d for those with a body weight of > 75 kg.
Chronic hepatitis C was diagnosed based on the detection
of serum HCV-RNA. Each patient was positive for anti-HCV
antibody by a third-generation enzyme-linked immunosor-
bent assay. Patients were excluded if they tested positive for
serum hepatitis B surface antigen or anti-human immunode-
ficiency virus antibody or exhibited other causes of hepato-
cellular injury (e.g., a history of alcoholism, autoimmune
hepatitis, primary biliary cirrhosis, or treatment with hepa-
totoxic drugs). Qualitative HCV RNA was detected with a po-
lymerase chain reaction (PCR)-based assay (Cobas Amplicor
Hepatitis C Virus Test, version 2.0; Roche Molecular Systems,
Branchburg, NJ, USA), which has a lower limit of detection of
approximately 50 IU/mL.HCVRNAwasquantifiedusinga real-
time PCR-based assay (COBAS AmpliPrep/COBAS TaqManHCV
Test; Roche), dynamic range: 43e69,000,000 IU/mL. HCV
genotyping was performed using the Siemens Diagnostics
Versant HCV Genotype Assay (Munich, Germany).
Ethical approval
This studywas incompliancewith theHelsinkiDeclarationand
was approved by the Institutional Review Board of Kaohsiung
ChungGungMemorial Hospital.Written informedconsentwas
obtained from each of the participants in this study.
PBMC preparation and RNA extraction
PBMCs were isolated from peripheral venous blood of the
patients before antiviral therapy with Ficoll-Hypaque den-
sity gradient centrifugation. Total cellular RNA was
extracted using the Trizol RNA Extraction Kit (Invitrogen,
Waltham, Massachusetts, USA) in accordance with the
manufacturer’s instructions. RNA yield and purity were
determined spectrophotometrically at 260/280 nm.
Multiplex reverse transcription-PCR analysis for
JAK/STAT signaling transcripts
Twenty patients with SVR and 20 patients without SVR were
randomly selected for a multiplex reverse transcription
(RT)-PCR analysis for JAK/STAT signaling transcripts
(Applied Biosystems, Waltham, MA, USA). One-step RT-PCR
Table 1 Univariate analysis of baseline characteristics of
sustained virological response and nonsustained virological
response patients for those who received multiplex reverse
transcription-polymerase chain reaction analysis Jak ki-
nase/signal transducers and activators of transcription
signaling transcripts.
Variables SVR (N Z 20)a Non-SVR
(N Z 20)a
pa
Sex (male:female) 9:11 6:14 0.327
Age (yr) 52.5  14.4 53.9  9.4 0.715
BMI, Kg/m2 24.8  4.1 24.9  3.6 0.931
ALT (IU/L) 131.3  128.6 86.8  53.8 0.176
HCV viral load
( 4  105 IU/mL vs.
< 4  105 IU/mL)
14:6 14:6 1.000
Liver cirrhosis
(yes vs. no)
1:19 5:15 0.182
RVR (yes vs. no) 10:10 7:13 0.337
RQ (SOCS1) 2.14 1.00
ALT Z alanine aminotransferase; BMI Z body mass index;
HCV Z hepatitis C virus; RQ Z relative quantification;
RVR Z rapid virological response; SOCS1 Z suppressor of the
cytokine signaling 1; SVR Z sustained virological response.
a Data are shown as mean  standard deviation.
442 C.-M. Lee et al.was used to profile 96 mRNAs reflecting the expression of 96
human genes that belong to JAK/STAT signaling pathways
along with a “housekeeping” gene (GAPDH ).
Gene expression values were calculated based on the
DDCt method, resulting in a relative expression level as
follows: relative abundance of genes Z 2(eDCt), where DCt
is the difference between the Ct of the target and the
arithmetic mean Ct of the reference genes. Genes were
considered significantly expressed and their transcripts
measurable if their corresponding Ct value was  35 and
the DCt between duplicates was  1. Modulation of
expression was assessed based on the following criteria:
minimal fold change of 1.8 (corresponding to 1.8 for upre-
gulation and 0.56 for downregulation). The detailed
methods for multiplex RT-PCR were described previously.19
Analysis of mRNA expression in peripheral blood
Genes that were upregulated or downregulated based on
the human JAK/STAT customized TaqMan array analysis
were further validated in a sample of 100 patients. To
quantify mRNA levels in peripheral blood, RT-PCR was
performed with LightCycler 2.0 (Roche Diagnostics GmbH,
Mannheim, Germany). The reagent mixture was prepared
according to the protocol provided by the manufacturer
(Roche Diagnostics GmbH). The total RNA (2 mg) was
extracted from PBMCs to generate cDNA sequences using
oligo (dT)18 primers (GeneMark, Taipei, Taiwan). PCR was
performed using a reaction mixture (10 mL) containing
LightCycler Fast Start DNA Master SYBR Green I mix (1 mL),
forward and reverse primers (0.5mM each), and cDNA (2 mL).
The conditions for the amplification and detection of se-
quences were as follows: one cycle of 95C for 10 minutes
and 40 cycles of 95C for 10 seconds, 62C for 5 seconds,
and 72C for 8 seconds. After amplification was complete, a
final melting-curve analysis was performed by denaturation
at 95C, cooling at 65C for 15 seconds, and finally slow
heating (0.1C/s) until reaching 95C. Data were analyzed
using LightCycler Software 4.1 (Roche Diagnostics GmbH).
Ct represents the threshold cycle value; DCt Z Ct (target
gene) e Ct (GAPDH ). The expression of target genes in
each sample was tested in triplicate. The mRNA expression
levels of target genes are shown as DCt.
Statistical analysis
Differences between virological responders and non-
responders were compared using Chi-square tests and Stu-
dent t tests. Independent factors that may have influenced
the response to combination therapy were identified using
a stepwise multiple logistic regression analysis. A p value of
< 0.05 was considered statistically significant.
Results
Multiplex RT-PCR analysis for JAK/STAT signaling
transcripts
We randomly selected 20 SVR patients and 20 non-SVR pa-
tients for a multiplex RT-PCR analysis of JAK/STAT signalingtranscripts. The baseline characteristics of the patients are
summarized in Table 1. There were no significant differ-
ences in age, sex, body mass index, alanine aminotrans-
ferase, viral load, cirrhosis, and rapid virological response
between the two groups. Suppressor of cytokine signaling 1
(SOCS1) was upregulated in SVR patients compared with
non-SVR patients (relative quantification Z 2.14)
(Supplementary Table 1).Baseline characteristics of all patients
We further analyzed SOCS1 expression in 100 patients.
Sixty-three patients achieved SVR, 37 patients did not. We
found that SOCS1 expression was not significantly different
between SVR and non-SVR patients. The proportion of pa-
tients with rs 12979860 CC genotype was significantly higher
in the SVR group compared with non-SVR group patients
(pZ 0.003) (Table 2). Multivariate analysis for SVR showed
that rs12979860 genotype CC is an independent predictor
for SVR (odds ratio: 4.69, 95% confidence interval:
1.74e12.62; p Z 0.002).Discussion
Previous studies have shown that HCV-infected patients
who express the SOCS1 gene in PBMCs have a better chance
of achieving SVR than patients who do not express the
gene.17,20,21 These results are consistent with our initial
finding that SOCS1 expression is upregulated in SVR patients
compared with non-SVR patients based on a multiplex RT-
PCR analysis. However, SOCS-1 expression did not differ
between SVR and non-SVR patients in the large sample of
100 patients. This may be explained by a selection bias; we
Table 2 Univariate analysis of baseline characteristics of
sustained virological response and nonsustained virological
response in all patients.
SVRa Non-SVRa pa
Age (yr) 59.0  8.7 60.8  9.4 0.335
Sex (male:female) 29:34 14:23 0.424
Liver cirrhosis (yes;no) 11:52 4:33 0.369
Viral load (:<400,000 IU) 43:20 26:11 0.833
AST (IU/L) 78  60 69  38 0.412
ALT (IU/L) 140  210 84  52 0.120
Bilirubin (mg/dL) 0.8  0.4 0.8  0.4 0.713
AFP (ng/mL) 8.1  9.7 9.5  10.7 0.499
DCt 7.7  1.2 7.9  1.1 0.500
rs 12979860 (CC:non-CC)b 55:8 22:15 0.003
ALT Z alanine aminotransferase; AFP Z a-feto protein;
AST Z aspartate aminotransferase; SOCS1 Z suppressor of the
cytokine signaling 1; SVR Z sustained virological response.
a Data are shown as mean  standard deviation.
b The SOCS1 mRNA expression was shown as DCt. DCt Z Ct
(SOCS1) e Ct (GAPDH).
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those who provided informed consent.
Other studies have reported that SVR rate is inversely
related to SOCS-3 and SOCS-1 levels in the liver.22e26 The
inconsistent results regarding SOCS-1 expression and its
correlation with SVR may reflect differences in SOCS-1
expression between the liver and peripheral blood.
Viral infections induce the expression of negative reg-
ulators of the IFN signaling pathway, such as SOCS1, which
is associated with and inactivates JAK, inhibiting the
phosphorylation of both IFN-a receptor and STAT pro-
teins,27,28 and downregulates the transcription of IFN-
stimulated genes.29 Conversely, transfection of the HCV
core protein in mouse liver silences SOCS-1 transcription,
leading to permanent activation of the JAK/STAT signaling
pathway.30 Other studies suggest that the presence of
SOCS-1 and SOCS-3 inhibits IFN-mediated antiviral and
antiproliferative activity during HCV infection, which in-
terferes with exogenous IFN administration.31,32 Tran-
scriptional silencing of the SOCS1 gene in the liver is a
potential explanation for treatment failure in HCV-
infected patients as well as in the mouse model of
chronic HCV infection.30 In both instances, silencing of
SOCS1 leads to permanent activation of the JAK/STAT
signaling pathway.30 All of these studies suggest that
SOCS1 plays an important role in the innate immune
response and may be a predictor of SVR.
This study had several limitations that are worthy of
mention. Firstly, we did not consecutively enroll patients;
in contrast, we only enrolled those who were willing to sign
informed consent. Secondly, the standard treatment dura-
tion of PEG-IFN and RBV for patients with HCV genotype 1
infection is 48 weeks. Owing to the reimbursement policy of
the Bureau of Taiwan National Health Insurance, all
enrolled patients in this study with HCV genotype 1 in-
fections received response-guided therapy for only
24e48 weeks. Thirdly, the case number is too small in this
study.In conclusion, peripheral blood SOCS1 expression is not
associated with SVR in HCV genotype 1 patients treated
with PEG-IFN-a and RBV. The effect of SOCS1 on treatment
responses merits further investigation.Acknowledgments
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